Also known as: LY3502970, OWL-833
Weight management in adults with obesity or overweight
Amount
6 mg, 12 mg, or 36 mg
Frequency
Once daily
Duration
72 weeks (Phase 3)
Route
OralTiming
Taken once daily as an oral capsule; no food or water restrictions required; dose escalation used to minimize GI side effects
Duration
Ongoing (long-term use intended)
Repeatable
Yes
Fasting glucose and HbA1c
When: Baseline
Why: Baseline glycemic status
Lipid panel
When: Baseline
Why: Baseline cardiovascular risk markers
Fasting glucose and HbA1c
When: 12 weeks
Why: Monitor glycemic changes
Lipid panel
When: 24 weeks
Why: Assess metabolic improvements
Get free access to all content plus biweekly research updates.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Orforglipron (LY3502970, formerly OWL-833) is an oral, non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and Company. Originally discovered by Chugai Pharmaceutical and licensed to Lilly in 2018, orforglipron represents a fundamentally different approach to GLP-1 receptor activation compared to existing peptide-based therapies such as semaglutide and tirzepatide.
With a molecular weight of approximately 883 Da, orforglipron is a synthetic small molecule rather than a modified peptide. This distinction is clinically significant: orforglipron can be taken as a once-daily oral capsule without the food and water timing restrictions required for oral semaglutide (Rybelsus), and it avoids the need for subcutaneous injection entirely. The non-peptide nature also enables simpler chemical synthesis manufacturing compared to peptide production, potentially reducing costs and improving supply scalability.
Orforglipron is currently in Phase 3 development through the ATTAIN clinical trial program, with regulatory submissions initiated in 2025.
Orforglipron is a full agonist of the human GLP-1 receptor, activating the same signaling pathways as the endogenous incretin hormone GLP-1 and peptide-based GLP-1 receptor agonists.
Despite being a non-peptide small molecule, orforglipron binds to the GLP-1 receptor and stimulates downstream signaling including:
Orforglipron achieves once-daily oral dosing through favorable pharmacokinetic properties:
Orforglipron has been evaluated in Phase 1, Phase 2, and Phase 3 clinical trials encompassing both obesity and type 2 diabetes populations.
The pivotal Phase 2 trial (Frias et al., NEJM 2023) randomized 272 adults with obesity or overweight to orforglipron 12, 24, 36, or 45 mg daily or placebo for 36 weeks. At week 36, mean weight loss ranged from 9.4% to 14.7% with orforglipron versus 2.3% with placebo. At the 36 mg dose, 75% of participants achieved at least 10% weight loss.
The ATTAIN-1 trial randomized 3,127 adults with obesity to orforglipron 6, 12, or 36 mg daily or placebo for 72 weeks. The 36 mg dose produced 11.2% mean weight loss versus 2.1% with placebo. Among patients receiving 36 mg, 54.6% achieved at least 10% weight loss and 18.4% achieved at least 20% weight loss. Significant improvements in waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol were also observed.
The ATTAIN-2 trial evaluated orforglipron in adults with obesity and type 2 diabetes across 136 sites. The 36 mg dose achieved 9.6% mean weight loss at 72 weeks, with HbA1c reductions of 1.3-1.8% from a baseline of 8.1%.
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity, published in New England Journal of Medicine (Frias JP et al., 2023; PMID: 37351564):
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1), published in New England Journal of Medicine (Aronne LJ et al., 2025; PMID: 40960239):
Orforglipron for the Treatment of Obesity in People with Type 2 Diabetes (ATTAIN-2), published in The Lancet (Horn DB et al., 2025; PMID: 41275875):
Orforglipron (LY3502970), a Novel Oral Non-peptide GLP-1 Receptor Agonist: Phase 1a Study in Healthy Participants, published in Diabetes, Obesity and Metabolism (Pratt EJ et al., 2023; PMID: 37344954):
We summarize new studies, safety updates, and dosing insights โ delivered biweekly.
See real-world usage patterns alongside the clinical evidence above. Community-sourced, not clinically verified.
0View community protocolsMazdutide: Dual GLP-1/glucagon agonist approved in China for obesity. Covers up to 20% weight loss in trials, mechanism, dosing, and side effects.
Retatrutide: Triple GIP/GLP-1/glucagon agonist with up to 24% weight loss. Covers mechanism, Phase 2/3 trial data, dosing, and side effects.
Ribupatide (HRS9531): dual GLP-1/GIP agonist by Hengrui/Kailera. Injectable showed 21.1% weight loss at 36 weeks. Oral 12.1% at 26 weeks. Phase 3 underway.
Semaglutide: FDA-approved GLP-1 agonist for weight loss and diabetes. Covers STEP/SUSTAIN trials, Ozempic vs Wegovy dosing, and cardiovascular benefits.
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.
Aleniglipron and orforglipron are the two leading oral non-peptide small molecule GLP-1 agonists, competing directly for the same market. Aleniglipron's ACCESS Phase 2b data is numerically impressive (11.3% placebo-adjusted at 120 mg in 36 weeks, and up to 15.3% at 240 mg), suggesting it may match or exceed orforglipron's ATTAIN-1 results (12.4% mean at 72 weeks). However, orforglipron is further ahead in development with completed Phase 3, filed FDA submission, and the backing of Eli Lilly. The higher GI event rates with aleniglipron (65% nausea) versus orforglipron's profile are a concern, though dose optimization may improve tolerability. The oral GLP-1 space is poised for intense competition once both agents reach the market.
Orforglipron represents a potential paradigm shift as the first oral non-peptide GLP-1 agonist without fasting restrictions, and it demonstrated superiority over oral semaglutide in the head-to-head ACHIEVE-3 trial for both HbA1c and weight loss. However, injectable semaglutide (2.4 mg) still produces greater absolute weight loss (14.9% vs 12.4%) and has proven cardiovascular benefit from SELECT, plus years of real-world safety data. The choice depends on whether oral convenience or maximum proven efficacy is the priority.
Tirzepatide delivers substantially greater weight loss (20.9% vs 12.4%) through its dual GIP/GLP-1 mechanism and is FDA-approved with a large evidence base. Orforglipron offers the unique advantage of unrestricted oral daily dosing, eliminating the need for injections entirely. The ATTAIN-MAINTAIN trial validated that patients can switch from tirzepatide to orforglipron and maintain their weight loss, establishing a potential sequential treatment paradigm: injectable first for maximum loss, then oral maintenance.
Orforglipron has the stronger evidence base with completed phase 3 trials (ATTAIN program) and NEJM publication. VK2735 has only phase 2 oral data but showed faster weight loss in a shorter timeframe and offers dual GLP-1/GIP agonism versus orforglipron's single GLP-1 target. Both represent the future of oral obesity treatment. Orforglipron's small-molecule design eliminates the need for special oral delivery technology, while VK2735's dual mechanism may provide enhanced efficacy. VK2735's additional injectable formulation provides a flexibility advantage. Neither is yet approved.
A comprehensive guide to every GLP-1 receptor agonist drug, from FDA-approved semaglutide and tirzepatide to pipeline therapies like retatrutide, amycretin, MariTide, and oral orforglipron.
Every GLP-1 and incretin drug ranked by clinical weight loss data as of 2026, from retatrutide at 28.7% to oral orforglipron at 11.2%, with comparison tables and trial details.
A comprehensive guide to every oral GLP-1 obesity drug in development, from approved oral semaglutide to pipeline agents orforglipron, aleniglipron, VK2735, ribupatide, and amycretin.
A comprehensive comparison of GI side effects across GLP-1 drugs, from semaglutide and tirzepatide to next-generation biased agonists like ecnoglutide and CT-388 that may improve tolerability.
Related content you may find interesting